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Abstract: 
This manuscript describes the model specification, including input and output measures, 
dependencies, and structure for VLSiM-PPW, a Monte Carlo type model for HIV adherence, viral 
load and vertical transmission in pregnant and breastfeeding women.  
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1 INTRODUCTION 
Viral load monitoring among people living with HIV (PLWH) is recognised as the gold standard for 
monitoring of treatment adherence and monitoring the development of treatment resistance [1]. 
There has been a rapid and wide scale up of viral load monitoring in low- and middle- income 
countries globally [2]. There are global concerns about adherence to ART in pregnant and 
breastfeeding women and subsequent elevated viral load (eVL) and mother-to-child-transmission 
(MTCT) risk [3]. Intensified viral load monitoring for pregnant and breastfeeding women has been 
proposed in some guideline recommendations but not evaluated systematically [4-6]. 
A simulation model for longitudinal HIV viral load (VL) during pregnancy and breastfeeding 
(VLSiM-PPW) has been developed to help evaluate guidelines based VL monitoring across a variety 
of individual and health system parameters [7]. The motivation and need for research in this area is 
considerable [3,8] and this model was created in response.  
This manuscript details the model specification, including input and output measures, 
dependencies, and outlines the calibration and validation approach.  
2 METHODS 
Overview of model specification  
Figure 1 describes the high-level model structure. A number of tables and schematics are presented 
to assist with understanding the model structure, as well as following text detailing the model 
structure and assumptions.  
 
 
Figure 1: ​Overview of model components with key constructs modelled 
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This is an individual, Monte Carlo type simulation model [9] simulating longitudinal antiretroviral 
therapy (ART) adherence, retention in care, HIV VL, breastfeeding and vertical transmission risk 
from conception until two years postpartum on a weekly time step. In addition to a number of 
individual parameters and outcomes, parameters at the level of health services are also modelled, 
including the possibility to: monitor VL, apply interventions of varying effectiveness and model the 
delay between timing of VL monitoring and return of test results. The overall objective of the model 
is to adequately simulate ART adherence, VL, and MTCT risk in pregnant and breastfeeding women 
in sub-Saharan Africa (SSA), in order to inform optimal VL monitoring schedules for early detection 
of raised VL during this period. The main outcome measures of interest are: the proportion of 
women becoming viremic over time, the proportion of women eligible for VL monitoring, the 
number of monitoring VL measurements taken, the median (IQR) of viral load at time of 
measurement, the cumulative viremia (cVL) experienced before detection, the number of 
interventions undertaken and the total number of vertical transmissions.  
Individuals can enter the simulation continuing, or initiating, ART and can be subject to different 
probabilities of adherence, different monitoring schedules and different impacts of intervention. 
Women can enter care at different gestational ages, and have a weekly risk of being lost to care. 
Detailed description of each of the model components can be found below. 
Description of model components 
Temporal phases ​As this model is oriented towards pregnant and postpartum women (PPW) the 
model is compartmentalized into four natural periods reflecting stages of pregnancy and 
postpartum: Period 1: from conception until entry into antenatal care (ANC), Period 2: from ANC 
until delivery, Period 3: from delivery until the cessation of breastfeeding (BF), Period 4: from the 
cessation of BF until the end of 24 months postpartum (Figure 2). Individuals are modelled through 
all four periods in a contiguous manner and on a consistent weekly time step. Although the model is 
focused on the use and utility of VL monitoring during antenatal and early infant care, Period 1 is 
necessary to completely model vertical transmission, as infants are at risk of HIV acquisition from 
early post conception through to the end of breastfeeding. Certain considerations and interventions 
are only available in specific periods. For example, infant prophylaxis and interventions aimed at 
breastfeeding duration are only available in Period 3. Most importantly, VL monitoring and any 
intervention is only possible during Periods 2 and 3, where women are assumed to be in antenatal 
or mother-child based services. As the model incorporates the possibility of lost to follow up (or 
non-engagement in care) (LTFU), it is possible for women/infants to be modelled in Periods 2 and 3 
without possibility of VL monitoring.  
3 
 
Simulation model of HIV viral load in pregnancy (VLSiM-PPW)      Lesosky et al. 
Figure 2: ​Temporal phasing of simulation model.  
 
Model inputs 
Model input parameters were considered in three classes:  
1. Fixed: these are internal and/or biological variables that are either fixed by definition (i.e., 
floor or ceiling thresholds for computational stability) or will be fixed after internal 
validation and will not change for sensitivity, calibration or data analyses. These are 
mentioned throughout, but primarily discussed in the validation & calibration sections.  
2. Optimized: these are internal variables that have been through the calibration process and 
are subject to goodness-of-fit evaluation across a variety of data sources. 
3. Input: these are parameters, usually population based, that will be selected and/or varied 
depending on the context of the question or population being modelled. These are the 
model inputs relevant to most investigators and will be the model inputs used to 
parameterize the model for evaluation of specific scientific questions. These input 
parameters are described in Table 1. 
 
Maternal adherence ​We use the term “adherence” or “maternal adherence” to refer to the 
spectrum of retention and adherence patterns that may be present after a woman has been 
diagnosed and initiated to ART. As is well described empirically [10-12], adherence to ART, or to any 
chronic medication, is a complex behavioral phenomenon. Individuals may choose to consistently 
take medication or not for a variety of reasons, for example, perceived stigma or side-effects, and 
they may accidentally fail to take medication at different times for an unrelated set of causes, for 
example, a lost or forgotten bag containing medication. Both individual behavioral characteristics 
and stochastic events can impact the week-to-week levels of ART circulating in an individual's 
bloodstream, and subsequently the levels of circulating virus. Broadly speaking these patterns of 
behavior and access (consistency of pill taking), in the absence of developing HIV drug resistance, 
lead to either well controlled VL or to poorly controlled VL (note that HIV drug resistance is not 
currently modelled directly but may be reflected by varying other parameters).  
This simulation model does not mimic the complex multifactorial causes of variation in adherence, 
but models the observed variability in VL under a minimal set of key parameters. This is done by 
assuming and assigning each individual a “baseline adherence” category, which is calibrated to 
observed rates of viremia during pregnancy and postpartum, but can be altered by changing input 
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settings. This initial category generates a baseline probability using a random draw from a Gaussian 
mixture distribution. The baseline adherence probability is allowed to change over time (eg 
different baseline adherence during pregnancy compared to postpartum) as well as undergo an 
attenuation effect on either side of delivery. The attenuation effect and different pre- and post- 
delivery baseline adherence probabilities are controlled by simple binary switches. The updated 
“weekly adherence” probability is predicted from a linear model incorporating baseline adherence 
probability, any intervention effect currently in action, the previous weeks VL and how long the 
individual has been adherent or not, as well as a stochastic additive noise effect. This resulting 
weekly adherence probability is categorised as below or above the threshold for ‘adherence’, and 
then informs the estimation of the current VL value.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1:​ Model inputs altering simulation population characteristics and details of simulation setup 
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Input parameter Description Range 
Characteristics of population of pregnant and BF women entering care 
Mean gestational age 
(weeks) at entry to ANC  
 
Gestational age simulated from a mixture distribution using the input 
mean GA as primary peak mean. Rejection sampling used to ensure GA 
does not fall out of range boundary (8 weeks - delivery) and is prior to 
delivery. 
8 – 38 weeks 
(or delivery) 
Mean duration of BF 
(weeks) 
BF duration for individuals is simulated from a mixture distribution 
taking input mean as primary peak. Rejection sampling used to ensure 
BF duration is non-negative. 
0 – 96 weeks  
Percent of women 
initiating BF 
Taken as input 0 – 100% 
Percent of women 
continuing ART 
Taken as input 0 – 100% 
Total percent of women 
LTFU antenatally 
Converted into a weekly, individual probability of LTFU. Every week, for 
each individual a Bernoulli random variable is generated with weekly 
LTFU probability, if a success then women is considered LTFU from the 
following week.  
0 – 100% 
Total percent of women 
LTFU postnatally 
Converted into a weekly, individual probability of LTFU. Every week, for 
each individual a Bernoulli random variable is generated with weekly 
LTFU probability, if a success then women is considered LTFU from the 
following week. 
0 – 100% 
Percent of women with 
very poor/no ART 
adherence 
Can be set above zero to fix a percentage of simulated women who 
never progress towards or maintain viral suppression.  
0 - 100% 
Percent of women with 
full adherence 
Can be used to set simulations with some percentage of women who 
maintain viral suppression throughout.  
0 – 100% 
Percent of women with 
poor/mixed ART 
adherence 
The remaining proportion of women  who are neither classed as ‘full’ or 
‘never’ adherent. Sum of the three must be 100%.  
0 – 100% 
Characteristics of health system 
VL monitoring delay Average time in weeks from when a VL is measured to when the result 
is available to be fed back to the woman  
0 - 16 weeks 
VL monitoring strategy  Taken as input (see Table 2 and Supplement Table 1) Varies 
Maternal intervention 
strategy  
Can set duration of effect and percent of women it will be effective in.  Varies 
Infant intervention 
strategy 
Three fixed options: none, ‘regular’ and ‘enhanced’. See text for details.  Varies 
BF: breastfeeding; GA: gestational age; LTFU: lost to follow up; ART: antiretroviral therapy; ANC: antenatal 
care 
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There are three categories of baseline adherence: “complete adherence”, “mixed adherence” and 
“non-adherence”, the proportion of women in each category is an input parameter. Complete 
adherence will result in rapid viral suppression and sustained maintenance of viral suppression, 
with low probability of transient or long term viremia. Similarly, non-adherence will result in a lack 
of viral suppression (sustained viremia) with a low probability of meeting low VL targets. The mixed 
adherence group represents a group that may experience periodic episodes of non-adherence, or 
may simply have adherence probabilities that fluctuate with a larger magnitude, hence causing VL 
to fluctuate as well. Maximum VL for each individual is established via a viral set point simulated as 
“pre-ART VL” in the simulation initiation. Figure 3 provides a schematic of modeled adherence and 
factors influencing adherence.  
 
 
 
Figure 3: ​Schematic representation of modeled adherence and factors influencing adherence 
 
VL trajectories ​VL values are initiated at the point of conception, after the assignment of continuing 
or initiating ART status and initialization of baseline adherence category. The initialization VL 
represents an individual's mean expected VL under no change in adherence probabilities or biology. 
The distributions of initial VL have been based on empirical data, and are subject to sensitivity 
analyses. There are three possible models for simulation of individual weekly VL, characterized by 
their mean trend: stationary, decreasing and increasing.  
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A stationary distribution for VL is used prior to ART initiation and/or when individuals reach the VL 
set point or viral suppression at less than or equal to 50 copies/mL. The pattern of VL change over 
time in the stationary distribution is one of random noise around a zero-slope trajectory. Random 
noise is magnitude dependent above 1000 copies/mL, at 𝛾* log10(VL) [13,14] where 𝛾 is a 
modifiable internal parameter subject to calibration. 
A decreasing trajectory, applied post ART initiation, and if/when individuals return to ART 
adherence after a period of non-adherence, demonstrates a mean decreasing trend of VL over 
time, including random noise. An increasing trajectory is used when individuals are non-adherent or 
lost to follow-up and no longer in care. The duration spent in each of these trajectories depends on 
the weekly adherence probability. As with the stationary distribution, the random noise added to 
the current VL calculation is magnitude dependent above 1000 copies/mL. 
The allowable change of VL from week to week is controlled by three model parameter settings: 
step size, variance and compression factor. Figure 4 demonstrates these and the different potential 
viral load trajectories. VL step size is considered a fixed VL parameter currently set at 0.5 log​10 
copies/mL. VL variance is magnitude dependent when VL >= 1000 copies/mL (eg an individual with 
a current log​10​ VL = 6 can see a larger increase or decrease in VL compared to an individual with a 
current log​10​ VL = 3.5). When VL < 1000 copies/mL the noise is no longer magnitude dependent, but 
set at 10% of current VL.  
 
 
Figure 4: ​Sample viral load trajectories. Panel A: initiation of ART to sustained viral suppression. 
Panel B: Initiation of ART followed by sustained low level viremia. Panel C: Initiation of ART followed 
by sustained loss of viral control.  
 
MTCT risk modelling ​MTCT risk is established by first setting a model input parameter that 
determines the per compartment overall transmission risk in an untreated population. The weekly 
MTCT risk is then modified by weekly maternal VL into a weekly transmission probability. Each 
week, a random binary value is drawn with the individual weekly transmission probability to 
determine if transmission has occurred. Once transmission has occurred, the individual is removed 
from the risk set. The model allows for three levels of VL based modification, where lower maternal 
VL reduced transmission risk in a stepped manner. The threshold and degree of reduction are set by 
8 
 
Simulation model of HIV viral load in pregnancy (VLSiM-PPW)      Lesosky et al. 
internal parameters that are subject to calibration. If BF is halted, the transmission risk is set to 
zero. These compression factors for transmission risk are modifiable and subject to sensitivity 
analyses. The influence diagram for transmission risk is in Figure 5.  
 
 
Figure 5: ​Influence diagram for primary model of MTCT risk 
 
VL monitoring  ​Monitoring of VL is defined as a health services level attribute, and the observed (or 
monitored) VL are flagged and tracked for later analysis. The basic set of assumptions are as 
follows: a VL can only be observed if the individual is retained in care (not LTFU) and if it is 
monitored, in which case the individual can have a responsive intervention applied (if the 
monitored VL meets a threshold). The delay between monitoring the VL and observing the VL is 
called the “VL cascade lag” and is an explicit parameter in the model. As an example, point-of-care 
VL monitoring would have a VL cascade lag equal to zero (so a raised VL could have an intervention 
applied in the same time step), while a health system with a VL cascade lag of eight weeks could 
only apply the intervention eight weeks after the VL was originally monitored. This has obvious 
implications in the presence of effective interventions. Individuals who have not yet entered care, 
or who have dropped out of care, by definition, cannot be monitored, nor can an intervention be 
applied to them (Figure 2). The VL monitoring scenarios are selected to provide useful information 
to stakeholders and span the range from weekly VL monitoring while a woman is in care, European, 
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WHO and African guideline monitoring schedules, and monitoring at all or some of routine ANC and 
PP visits (Table 2 and Supplement Table 1).  
VL monitoring optimization ​The timing and frequency of viral load monitoring will be optimized for 
one, two or three VL monitoring tests during pregnancy and breastfeeding. This will be done 
varying the monitoring lag time for a number of simulated populations.  
 
Table 2:​ Classes of modelled VL monitoring scenarios  
Scenario  Intervention options Motivation 
No VL monitoring 
 
No intervention Reflects what occurs given the population parameters 
and in the absence of monitoring/intervention. Used 
for all non-monitoring/intervention dependent 
calibration. 
No VL monitoring 
 
Intervention on pre-set 
schedule (ie routine ANC 
visits/other specified) 
How non-response or scheduled interventions change 
outcomes. This is an evaluation of applying 
interventions as per a schedule instead of in response 
to (raised) VL.  
Weekly VL 
monitoring 
 
Trigger intervention if 
elevated VL detected 
This is the “optimal” case and reflect monitoring to the 
most precise scale of the model. This is also a 
non-feasible and most expensive scenario, but will set 
an upper threshold on early detection. 
Guidelines 
monitoring  
Per guidelines (Supplement 
Table 1) 
Compare existing guidelines.  
Routine ANC visits 
 
Trigger intervention if 
elevated VL detected 
Evaluate care based on routine visits only. This will be 
done on a country specific basis as with guidelines 
based monitoring. 
 
 
Intervention effect ​This simulation model is mostly concerned with interventions that are applied 
in response to an observed raised VL, as guidelines in most SSA countries currently propose. The 
option is available to apply interventions across the simulated eligible population without any VL 
monitoring, and this scenario is modelled. Specific interventions are not modeled explicitly, but the 
impact of an intervention is modelled by changing an individual's probability of adherence and/or 
retention, which in turn impacts the current VL. Three classes of interventions are modelled: those 
that impact the probability of retention in care, those that directly impact the probability of 
adherence, and those that have a direct impact on infant transmission risk. Interventions are 
parameterized by the response proportion (percent of individuals that have a response to the 
intervention), the duration of response (which can attenuate over time), as well as any potential 
delay in application or effectiveness of intervention.  
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Maternal interventions will be applied as a theoretical intervention that can impact retention in 
care (reducing the weekly probability of LTFU), adherence (increasing the weekly probability of 
adherence) or both together. The effectiveness and duration of an intervention will be set by input 
parameters (eg. 50% of women will adopt intervention, and it will be effective for 7 weeks). The 
change to probability of retention or adherence is subject to calibration analyses and will be 
estimated from the literature. As interventions of this type are poorly understood, most model 
output looking at or using interventions will estimate effects for a range of scenarios.  If 
interventions are responsive to raised VL, then interventions can be applied either at scheduled 
visits (either routine or VL monitoring visits) depending on when the VL result is made available. 
Alternately, interventions can be applied routinely. Maternal interventions are available to be 
applied in both antenatal and breastfeeding periods.  
Infant interventions are available post-delivery and take only two forms, which is the possibility to 
apply infant prophylaxis or alter BF recommendations. Three levels of infant prophylaxis are 
possible: none, standard (based on 6 weeks of NVP), and enhanced (based on 12 weeks of dual drug 
therapy). BF can be stopped (with a lag).  
 
Retention in care ​Retention in care is only modelled from the point of ANC entry. Women can enter 
continuing ART, or enter and initiate ART. HIV testing and lag between entry into ANC and initiation 
of ART are not modelled, assuming, as is the case in many SSA countries, that Option B+ is in place 
(same day ART initiation). Women are subject to a weekly probability of LTFU which is calculated 
using model input parameters for the overall rate of LTFU during pregnancy and the overall rate of 
LTFU during breastfeeding. If LTFU, a woman is assumed to be non-adherent and VL and 
transmission risk will rise. There is no current option for women to re-engage with care at a later 
time point. If a woman is not retained in care, she is not available for VL monitoring or any other 
health services interventions.  
Monitoring and feedback lag ​In most health systems, the “turnaround time” from taking the VL 
sample to being able to act on the information in the sample may vary. While point of care (POC) VL 
is available, it is not widely distributed in SSA. Studies investigating turnaround time for routine VL 
monitoring in adult populations in SSA show that this can differ from a low of 72 hours in South 
Africa, to a high of 8-12 weeks reported in Malawi [15]. This is a modifiable input parameter. The 
system lag incorporates both the time to get the VL result from the lab, as well as time to re-book a 
woman for a visit. An example makes this clear. If a woman is scheduled to have her VL monitored 
at 34 weeks gestation, but the system lag is 4 weeks, the first point in time an intervention could be 
applied is 38 weeks (noting that this may or may not be prior to delivery). This system lag clearly 
impacts the utility of VL monitoring, as long system lags are likely to result in higher rates of 
misclassification and missed opportunities.  
 
 
 
Simulation Algorithm 
A brief version of the simulation algorithm is provided here.  
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1. Population level parameters are initialised (Population size, monitoring schedule, ANC entry 
characteristics, BF characteristics, baseline adherence distributions, pre-ART VL, proportion 
continuing ART). 
 
2. Tracking matrices and helper functions are initialised, and individual starting parameters for 
the whole population are estimated from sampling distributions (eg, individual VL values at 
simulation start are estimated, individual time of ANC entry and delivery are set). 
 
3. Individuals are simulated sequentially; each individual simulation is independent allowing 
easy parallelisation.  
a. Conception to entry to ANC​ involves maintenance of initial parameters around a 
mean. No VL monitoring or interventions are able to occur during this period since 
women are not engaged in health care. MTCT is possible and tracked.  
 
b. ANC to delivery​. For women continuing ART, LTFU, VL monitoring and other 
interventions are able to occur. For women initiating ART, a VL suppression 
trajectory is started, subject to adherence, and/or LTFU. VL monitoring and 
interventions are able to occur. Delivery occurs at the modelled gestational age. 
MTCT can occur and is tracked. 
 
c. Delivery until end of BF ​. Adherence and LTFU rates subject to change on account of 
delivery. Women can breastfeed for a variable period of time. LTFU, VL monitoring 
and maternal interventions are available. Infant interventions are available  (infant 
prophylaxis). MTCT can occur and is tracked.  
 
d. End BF until 2 years P​P if not reached. Primarily model bookkeeping. MTCT cannot 
occur during this period, nor can any interventions be applied. LTFU no longer 
modelled (all model outcomes  are estimated at end of BF at latest).  
 
          4.  After full population has completed, summaries are tabulated per the model outcome 
measures. 
 
Outcome measures ​The main outcome measures of interest include: the proportion of women 
eligible for VL monitoring, the proportion of women viremic over time, the number of monitoring 
VL measurements taken, the median (IQR) of viral load at time of measurement, the cumulative 
viremia (cVL) experienced before detection, the number of interventions applied and the total 
MTCT rate. These are detailed in Table 3.  
 
 
Table 3:​ Model outcome measures 
Primary outcome measure Notes / time periods / groups 
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MTCT per 100,000 live births Cumulative until birth, cumulative until 6 weeks PP, 
cumulative until end BF 
Proportion women with VL>1000 copies/mL 
among women retained in care 
Before delivery; after initial viral suppression; cumulative to 
end BF 
Secondary outcome measures 
Proportion of women eligible for VL 
monitoring 
Must be retained in care at monitoring time point, and either 
not delivered or still BF depending on period 
Number of VL tests done Antenatal, postnatal, cumulative 
Median number of VL tests done per woman Antenatal, postnatal, cumulative 
Proportion of women with any VL test  Antenatal, postnatal, cumulative 
Median weeks to first VL test  Separately among continuing ART and initiating ART groups 
Median weeks to detection of raised viremia Product limit estimate of time to detection if monitored when 
VL elevated (those not monitored or not detected are 
considered censored at end of followup) 
Proportion of women with VL monitoring 
carried out at the time of elevated VL>1000 
copies/mL 
Antenatal, postnatal, cumulative 
Cumulative VL from 1st ANC until detection of 
VL>1000 copies/mL or 2y PP 
Separately among continuing ART and initiating ART groups 
Cumulative VL from first viral suppression until 
detection of VL>1000 copies/mL or 2y PP 
Separately among continuing ART and initiating ART groups 
PP - postpartum, BF - breastfeeding, ANC - antenatal care, MTCT - mother-to-child transmission 
 
 
Study design and sample size considerations 
As the simulation model is complex, including a large number of parameters, a formal study design 
for validation and calibration [16], as well as sample size calculations, were carried out.  
Two sample size calculations were considered. The first is the minimum population size for a single 
run of the simulation. This sample size was estimated based on the desire to estimate the primary 
and secondary model outcomes with specified relative precision. The MTCT transmission rates can 
be expected to vary from <1% in a population with good access to ART and other health services, to 
upwards of 40% in an untreated population. To estimate a difference of 0.005 when MTCT 
transmission rate is low (ie between 1% and 4%) with 95% power and an alpha of 0.008 (crudely 
adjusted for the six specified primary outcomes) requires a minimum sample size of N = 9157. To 
estimate a difference of 0.005 when MTCT transmission rate is high (eg between 30% and 40%) 
with 95% power and an alpha of 0.008 required a sample size of N = 177,639. This sample size was 
deemed too large for feasibility reasons, and precision with higher rates of MTCT transmission is of 
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less importance, so a 1% precision was evaluated, requiring a minimum sample size of N = 44,493, 
rounded up to N = 50,000.  A sample size of N = 50,000 will be used for all simulation runs where 
MTCT transmission will be estimated. Where MTCT transmission rates are not estimated or utilised 
(in some planned analyses investigating time to detection of raised viremia), the sample size was 
set at N = 10,000.  
The second calculation is the number of replicates to be run for each parameter set. For this we 
followed the approach in Law and Kelton [17] where pilot simulations are run (varying only the 
random seed) until the precision of the output estimate (mean and standard deviation) is within a 
specified range. This procedure and results comprise part of the validation and calibration analyses 
and will be detailed in a forthcoming calibration document.  
Other design considerations can be found in the sections pertaining to validation and calibration.  
 
3 MODEL VALIDATION AND CALIBRATION 
Model validation, sensitivity analyses and calibration are planned and extensive enough that full 
specification and results will be detailed in a different document. The main input parameters 
setting the population characteristics are: mean gestational age (weeks) of women at entry into 
ANC, the mean duration (weeks) of BF, the proportion of women entering ANC continuing ART, the 
total proportion of women LTFU in ANC and postpartum, the proportion of women with poor 
and/or mixed ART adherence. 
Internal model calibration ​  Internal model validation will use a contributed data source ‘MCH-ART’ 
[18] to set the ‘baseline parameters’. The model parameters (Table 4) will be altered until there is 
good agreement between the proportion of women viremic at different points during pregnancy 
and breastfeeding in the empirical data and the model generated outputs, the distribution of VL 
values among those not virally suppressed over time and the MTCT rate at delivery, 6 weeks 
postpartum and until the end of breastfeeding.  
 
Sensitivity analysis  ​After internal model validation, sensitivity analysis will be undertaken for key 
internal parameters in order to better understand the scope of model variability. The baseline 
values will be set after internal model calibration.  
 
The analysis plan for this section will involve calculating the parameter space of all possible 
combinations from parameters in Table 4, taking a subsample based on a latin square design [19] 
and running simulations with those settings. The MTCT and VL outcomes will be plotted for visual 
evaluation, and a goodness of fit measure will be calculated.  
 
Calibration  ​The simulation model will be calibrated on key variables across a number of 
contributed data sources. These represent the most comprehensive and best available empirical 
data globally on VL in PPW. This includes datasets from South Africa (MCH-ART [18] and National 
Health Laboratory Services), and Botswana (the Mma-Bana study [20]), as well as the largest PMTCT 
trial examining ART in pregnancy set in Uganda, the PROMISE study [21,22] .  
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MCH-ART 
A randomised control trial conducted in South Africa evaluated two delivery alternatives of HIV 
services to HIV infected breastfeeding women. The study was conducted in a peri-urban area in 
South Africa between 2015 – 2018. The current standard of care for HIV infected postpartum 
women, referral from the antenatal clinic at 4-8 weeks postpartum to the general adult ART 
services, was compared to continued maternal-focused ART services at the antenatal clinic 
throughout the period of breastfeeding. Maternal HIV viral suppression and retention in care up to 
12 months postpartum were evaluated [18]. 
 
NHLS 
Individuals undergoing HIV treatment in public sector facilities in the Western Cape province, South 
Africa, have routine blood samples processed by the National Health Laboratory Services (NHLS) in 
one of two laboratories.  NHLS data has previously been used to evaluate effectiveness of 
government funded HIV programs.  
 
Mma-bana 
A randomised control trial conducted in Botswana from July 2006 to May 2008, followed mother 
infant pairs on three different ART regimens. HIV infected ART naive women (n = 730) between 26 
and 34 gestation weeks were randomised to either abacavir, zidovudine, lamivudine (Arm A) or 
lopinavir–ritonavir, zidovudine–lamivudine (Arm B) and followed up to 6 months postpartum. The 
third arm was observational, where women with a CD4 cell count below 200 received 
nevirapine–zidovudine–lamivudine [20]. All women received multiple VL tests during follow up.  
 
PROMISE 
PROMISE (1077BF/FF) was a randomised control trial comparing the risk of placental malaria among 
lopinavir and efavirenz study arms. The study was conducted in rural Uganda, from December 2009 
to March 2013 and enrolled 389 HIV infected pregnant women [21]. A subset (n=200) of the women 
that participated in the PROMISE P2 study, were invited to partake in an observational study (BC2). 
The study assessed maternal viral suppression and retention in care up to 5 years postpartum [22]. 
 
Each simulation run to calibrate VL over time will be evaluated on each data set using a goodness of 
fit test described below.  
 
The basic algorithm is:  
1. Identify large parameter set to start (selected subset from sensitivity analysis). 
2. Run simulations for all parameter sets in 1. 
3. Select parameter sets to carry forward IF % viral suppression at delivery is within 5% of the 
data source measure of % viral suppression at delivery.  
4. If NO postnatal data then compare % viral suppression at antenatal time point between 
entry to ANC care and delivery. This will vary depending on the data set, and retain 
parameter sets within 5% of data source. 
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5. If postnatal data is available, then compare % viral suppression at 3m postpartum and retain 
parameter sets within 5% of data source. 
 
The retained parameter sets will be evaluated with a goodness of fit test to find the ‘best’ 
parameter set for a given data source. The root mean square error (RMSE) for the goodness of fit 
test  is found in equation (1).  
 
RMSE =  √∑
T
t=1
 T
(V S (t) − V S (t))P D
2
(1) 
 
The RMSE is calculated as the square root of the average of the squared difference between 
observed and projected proportion of women with VL <1000 copies/mL at each time point available 
in the source data, denoted by VS(t).  
 
 
4 CONCLUSION 
The detailed rationale, motivation and design considerations for the VL-SiM PPW simulation model 
are presented. Statistical considerations around design, sample size and feasibility are addressed 
and the current model algorithm is presented.  
To our knowledge, there are no individual stochastic simulation models that incorporate 
longitudinal adherence and VL trajectories in pregnant and breastfeeding HIV+ women. This model 
presents a novel opportunity to simulate patterns of VL in an important population to understand 
the role and impact of VL monitoring on detection and intervention for the prevention of vertical 
transmission.  
 
 
 
 
 
 
 
 
 
 
 
Table 4:​ Model input and other parameters for sensitivity and calibration analyses 
Parameter Description 
Mean gestational age at ANC 
entry 
Impacts the average duration of treatment for those initiating ART during 
pregnancy 
Percentage women initiating ART Modifies the population proportion continuing or initiating ART during 
16 
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during antenatal care pregnancy 
Proportion ‘full’ adherent Controls the percentage of women considered to be adherent sufficient to 
sustain viral suppression 
Proportion ‘partial’ adherent Controls the percentage of women with adherence that is not always 
sufficient to sustain viral suppression, but who have intermittent patterns 
of adherence 
Mean duration breastfeeding Modifies the average duration of breastfeeding 
Percentage women LTFU Controls the overall proportion of women LTFU (antenatal and postnatal) 
Distribution ‘pre-ART’ viral load Alters the incoming VL distribution of women initiating ART 
Viral load ‘step size’ Controls the mean allowable change in VL from week to week 
Viral load ‘noise’ Controls the magnitude of additive noise on change in VL from week to 
week 
Adherence ‘noise’  Controls the magnitude of additive noise on change of adherence from 
week to week 
MTCT risk period 1 Early antenatal vertical transmission risk in an untreated population 
MTCT risk period 2 Peripartum vertical transmission risk in an untreated population 
MTCT risk period 3 Early breastfeeding vertical transmission risk in an untreated population 
MTCT risk period 4 Late breastfeeding vertical transmission risk in an untreated population 
MTCT risk compression factors Modifies the VL - risk dose dependence 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5 : ​Details of guidelines based monitoring at the time of writing. Additional monitoring 
guidelines may be added as they become available.  
Guideline 
(year)  [ref] 
VL monitoring time points antenatal  VL monitoring time points 
breastfeeding 
WHO (2016) 
[1] 
If initiating ART: 6m, 12m, then annually and at 34-36 weeks GA  
 
Annually 
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If continuing ART: annually from ART initiation date and at 34-36 
weeks GA 
USA DHHS 
(2018) [23]  
If initiating ART: 2-4 weeks after ART initiation, then monthly until 
VS, then 3 monthly (if VL,50 copies/ml) plus at 34-36 weeks GA 
 
If continuing ART: 1st ANC visit and routinely every month, move to 
monitoring every 3 months (if VL<50 copies/ml) plus 34-36 weeks 
GA 
BF not recommended in 
this population 
UK (2018) 
[24] 
If initiating ART: 2-4 weeks post initiation, at least every trimester 
and at 36 weeks GA 
 
If continuing ART: at least every trimester and at 36 weeks GA 
BF not recommended in 
this population 
South Africa 
(2015) [4] 
If initiating ART: 3m, 6m then every 6m 
 
If continuing ART: first ANC, every 6m 
Continue every 6m until 
end of BF 
Kenya (2016) 
[5] 
If initiating ART: 6m, then every 6m 
 
If continuing ART: first ANC, then every 6m 
Continue every 6m until 
end of BF 
Malawi 
(2016) [25] 
If initiating ART: 6m, then every 24m 
 
If continuing ART: every 24m 
Continue every 2y until 
end BF 
Uganda 
(2016) [26] 
If initiating ART: 6m post ART, then annually 
 
If continuing ART: first ANC, 6m, then annually 
Continue annually until 
end BF 
Zambia 
(2018) [6] 
If initiating ART: 6m, then every 6m plus at 34-36 weeks GA 
 
If continuing ART: first ANC, then every 6m plus at 34-36 weeks GA 
Continue every 6 m until 
end BF 
BF: breastfeeding; ANC: antenatal care; ART: antiretroviral therapy; WHO: World Health Organisation; GA: 
gestational age  
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